Apyx Medical Corporation (NASDAQ:APYX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Apyx Medical Corporation (NASDAQ:APYX) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.50.

APYX has been the topic of a number of research analyst reports. BTIG Research raised shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Wednesday, March 11th. Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Craig Hallum raised their target price on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Friday, March 27th.

Apyx Medical Price Performance

Shares of NASDAQ:APYX opened at $4.13 on Monday. Apyx Medical has a 12 month low of $1.41 and a 12 month high of $4.50. The company’s 50-day moving average price is $3.77 and its two-hundred day moving average price is $3.77. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68. The firm has a market cap of $172.92 million, a P/E ratio of -18.77 and a beta of 1.35.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million for the quarter, compared to analyst estimates of $10.53 million.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of APYX. AIGH Capital Management LLC bought a new position in shares of Apyx Medical in the 4th quarter valued at about $3,867,000. Nantahala Capital Management LLC boosted its stake in shares of Apyx Medical by 19.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after purchasing an additional 636,043 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares during the last quarter. Informed Momentum Co LLC bought a new position in shares of Apyx Medical in the 4th quarter valued at about $863,000. Finally, Huntleigh Advisors Inc. bought a new position in shares of Apyx Medical in the 4th quarter valued at about $827,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.